Sramana Mitra: We have a lot of activity right now in Europe. Recently in the last Fall, we announced a partnership with EIT Health. These are all healthcare IT companies. That’s probably aligned with your investment thesis. How about a few examples of deals that you have invested in and a little bit of a
Sramana Mitra: Let’s say we send you a company. You will figure out from your network who is the likely investor that you want to do the deal with and have them price the deal and lead the deal. Is that what you’re saying? Frank Malek: Yes, we prefer that. That’s right. Sramana Mitra: You
Responding to a popular request, we are now sharing transcripts of our investor podcast interviews in this new series. The following interview with Frank Malek was recorded in January 2019. Frank Malek is General Partner at Impacteo, an impact investment fund that invests in companies in the US and in Europe. This includes companies in
Sramana Mitra: In your deal flow, what kind of trends are you seeing? Andrew Cain McClary: On the tools side of things, I feel like everyone feels it’s a prerequisite to put AI or machine learning in whatever they’re doing even when sometimes the datasets are not there for them to include that in a
Sramana Mitra: Just to double-click on what you said, would you fund a company that has a good level of technology and a good understanding of the business, but still needs another half a million to a million for product development? Andrew Cain McClary: Absolutely. The earlier in the stack I go, the better I
Responding to a popular request, we are now sharing transcripts of our investor podcast interviews in this new series. The following interview with Andrew Cain McClary of KdT Ventures was recorded in January 2018. Andrew Cain McClary, Founder and Managing Partner at KdT Ventures, is a physician-turned VC. The focus of his investment is biology and related
Sramana Mitra: In some cases if you can exit your company without needing a Series A, that is not a bad way to mitigate the Series A gap. Victoria Pettibone: Yes. Your angels are going to be happy for the most part. Even though it’s a short turnaround time, they will not have been diluted.
Sramana Mitra: Let’s talk about what you have invested in in your current portfolio. Maybe even exits. You talked about a couple of exits this year. One of them was an IT company. Victoria Pettibone: The two exits are both public. One was Ciel Medical which exited to Vyaire Medical. The other was Cloudamize, which